The U.S. government should look to other economically developed countries with a heavier hand in drug pricing in order to better wrangle drug prices, the authors of a recent article published on The Conversation write.
More government involvement in drug prices, however, has gained “little favor” in the U.S., the authors write.
“Many countries with universal health care or multipayer systems, or both, have national organizations responsible for conducting health technology assessments,” they write. “These generate evidence to support reimbursement decisions and price setting. Countries that do this include Australia, Canada, Germany, Ireland and the United Kingdom.”
To read the full article, click here.